Betha Ariesanty
Research Subjects
Betha Ariesanty has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Syahril
Sulianti Saroso Infectious Disease, Jakarta, Indonesia
2 shared publications - Siti Maemun
Research Team, Sulianti Saroso Infectious Disease Hospital; Department of Public Health, Faculty of Health Sciences, Universitas Respati Indonesia, Jakarta
2 shared publications Adiatmo Pratomo
Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia
1 shared publicationAninda Dinar
Sulianti Saroso Infectious Disease, Jakarta, Indonesia
1 shared publication- Anita Puspitasari
Sulianti Saroso Infectious Disease, Jakarta, Indonesia
1 shared publication - Christine Ernita
Sulianti Saroso Infectious Disease, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 29 September 2022
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 15 (3) , 1745-1749
Quantitative Antibody Levels in Hospital Workers after Receiving three Doses of CoviD-19 vaccines
Hospital workers were at high risk for SARS-CoV-2 infection and the first population with authorized access to the three doses of vaccination against SARS-CoV-2 antigen. The study was aimed to compare SARS-CoV-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso Infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-CoV-2 antibody levels measured by the Architect of SARS-CoV-2 IgG II Quant. There were 75 participants in the study, the median of anti SARS CoV-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, Interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p=1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). In this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection.
- 29 September 2022
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 15 (3) , 1745-1749
Open AccessQuantitative Antibody Levels in Hospital Workers after Receiving three Doses of CoviD-19 vaccines
Hospital workers were at high risk for SARS-CoV-2 infection and the first population with authorized access to the three doses of vaccination against SARS-CoV-2 antigen. The study was aimed to compare SARS-CoV-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso Infectious Disease Hospital (SSIDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-CoV-2 antibody levels measured by the Architect of SARS-CoV-2 IgG II Quant. There were 75 participants in the study, the median of anti SARS CoV-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, Interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p=1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month; 2 to 3 months; 4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL; 5778.1 AU/mL, respectively). In this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection.
- Open Access
- 30 December 2021
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 14 (4) , 2327-2335
The Use of Convalescent Plasma (CP) Transfusion Therapy in Moderate to Severe COVID-19 Patients: a Single Center Experience in Indonesia
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.
- 30 December 2021
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 14 (4) , 2327-2335
Open AccessThe Use of Convalescent Plasma (CP) Transfusion Therapy in Moderate to Severe COVID-19 Patients: a Single Center Experience in Indonesia
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.